期刊
FRONTIERS IN PHARMACOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2020.610880
关键词
biosimilar; liraglutide; pharmacokinetics; bioequivalence; safety
资金
- Deyang Science and Technology Program [FY202003]
- Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
The study demonstrated pharmacokinetic similarity between LRG201902 and Victoza(R) in healthy subjects, with comparable safety and immunogenicity profiles in the two products.
Objective: Pharmacokinetic (PK) similarity between biosimilar candidate LRG201902 and European Union-sourced liraglutide reference product (Victoza(R)) was evaluated. Safety and immunogenicity were also assessed. Methods: This single-dose, randomized, open-label, 2-period crossover study (CTR20192342) was conducted in thirty-eight healthy adult male subjects. Volunteers were randomized 1:1 at the beginning to receive a single 0.6 mg dose of Victoza(R) or LRG201902 by subcutaneous injection during the first period. Following 8 days washout period, all subjects received the alternate formulation during the second period. Blood samples were collected up to 72 h after administration. The primary pharmacokinetic endpoints were AUC(0-t), AUC(0-infinity), and C-max. Pharmacokinetic similarity was achieved if 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of AUC0-t, AUC(0-infinity), and C-max were within the range of 80-125%. Other pharmacokinetic parameters including T-max, t(1/2), and lambda(z) were also measured. Safety profile and immunogenicity data were collected from each subject. Results: C-max, AUC(0-t), and AUC(0-infinity) were similar between the two groups. GMRs of Cmax, AUC(0-t), and AUC(0-infinity) were 113.50%, 107.21%, and 106.97% between LRG201902 and Victoza(R) respectively. The 90% CIs for the GMRs of C-max, AUC(0-t), and AUC(0-infinity) were all within the PK equivalence criteria. Mean serum concentration-time profiles, secondary pharmacokinetic parameters (T-max, t(1/2), and lambda(z)) were comparable between groups. Treatment-related adverse events were reported by 27.8% and 23.7% subjects in the LRG201902 and Victoza(R) arms, respectively. All post-dose samples were detected negative for anti-drug antibodies. Conclusion: This study demonstrates pharmacokinetic similarity of LRG201902 to Victoza(R) in healthy subjects. The safety and immunogenicity profiles were similar for the two products.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据